Symbols / LYRA $0.49 +0.02% Lyra Therapeutics, Inc.

Healthcare • Biotechnology • United States • PNK
LYRA Chart
About

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 870.40K
Enterprise Value 15.24M Income -28.92M Sales 398.00K
Book/sh -2.63 Cash/sh 8.94 Dividend Yield —
Payout 0.00% Employees — IPO —
P/E — Forward P/E -0.50 PEG —
P/S 2.19 P/B -0.19 P/C —
EV/EBITDA -0.52 EV/Sales 38.28 Quick Ratio 1.67
Current Ratio 1.71 Debt/Eq — LT Debt/Eq —
EPS (ttm) -18.62 EPS next Y -0.99 EPS Growth —
Revenue Growth -96.70% Earnings 2025-11-12 16:00 ROA -36.06%
ROE -65.95% ROIC — Gross Margin 100.00%
Oper. Margin -987.29% Profit Margin 0.00% Shs Outstand 1.77M
Shs Float 396.24K Short Float 1.10% Short Ratio 0.35
Short Interest — 52W High 37.50 52W Low 0.31
Beta — Avg Volume 103.32K Volume 1.54K
Target Price — Recom None Prev Close $0.49
Price $0.49 Change 0.02%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.49
Latest analyst target
3. DCF / Fair value
$-201.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.49
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-08-14 reit HC Wainwright & Co. Neutral → Neutral $16
2025-06-10 main HC Wainwright & Co. Neutral → Neutral $16
2025-03-14 reit HC Wainwright & Co. Neutral → Neutral $2
2024-08-15 reit Cantor Fitzgerald — → Overweight —
2024-08-15 reit HC Wainwright & Co. Neutral → Neutral $2
2024-06-20 reit Cantor Fitzgerald — → Overweight —
2024-05-07 down HC Wainwright & Co. Buy → Neutral $2
2024-05-07 down Jefferies Buy → Hold $1
2024-05-06 down BTIG Buy → Neutral —
2024-05-01 reit HC Wainwright & Co. Buy → Buy $12
2024-03-25 main B of A Securities Buy → Buy $11
2024-03-22 reit HC Wainwright & Co. Buy → Buy $12
2023-10-02 reit HC Wainwright & Co. Buy → Buy $12
2023-09-12 main B of A Securities Buy → Buy $15
2023-08-31 init HC Wainwright & Co. — → Buy $12
2023-02-07 main BTIG — → Buy $20
2022-05-24 init Cantor Fitzgerald — → Overweight $15
2020-05-26 init B of A Securities — → Buy $21
2020-05-26 init Jefferies — → Buy $24
News
RSS: Latest LYRA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-06 PALASIS MARIA Chief Executive Officer — 1,702 $3.36 $5,726
2026-01-06 CAVALIER JASON Chief Financial Officer — 769 $3.36 $2,587
2025-11-13 PERCEPTIVE ADVISORS LLC Beneficial Owner of more than 10% of a Class of Security — 45,875 $3.90 $182,515
2025-11-10 PERCEPTIVE ADVISORS LLC Beneficial Owner of more than 10% of a Class of Security — 70,390 $4.54 $344,219
2025-07-10 PALASIS MARIA Chief Executive Officer — 1,565 $8.91 $13,944
2025-07-10 CAVALIER JASON Chief Financial Officer — 684 $8.91 $6,094
2025-01-08 PALASIS MARIA Chief Executive Officer — 800,000 — —
2025-01-08 CAVALIER JASON Chief Financial Officer — 420,000 — —
2024-10-16 PALASIS MARIA Chief Executive Officer — 300,000 — —
2024-10-16 CAVALIER JASON Chief Financial Officer — 100,000 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.40
-74.05%
1.53
-1.54%
1.56
+14.31%
1.36
Operating Revenue
0.40
-74.05%
1.53
-1.54%
1.56
+14.31%
1.36
Operating Expense
29.95
-51.90%
62.27
-7.18%
67.09
+19.05%
56.35
Research And Development
18.41
-57.93%
43.77
-8.88%
48.03
+23.80%
38.80
Selling General And Administration
11.54
-37.62%
18.50
-2.92%
19.06
+8.55%
17.56
General And Administrative Expense
11.54
-37.62%
18.50
-2.92%
19.06
+8.55%
17.56
Other Gand A
11.54
-37.62%
18.50
-2.92%
19.06
+8.55%
17.56
Total Expenses
29.95
-51.90%
62.27
-7.18%
67.09
+19.05%
56.35
Operating Income
-29.55
+51.34%
-60.73
+7.32%
-65.53
-19.16%
-54.99
Total Operating Income As Reported
-31.02
+67.80%
-96.35
-43.55%
-67.12
-19.21%
-56.31
EBITDA
-29.09
+51.72%
-60.26
+7.64%
-65.25
-21.01%
-53.92
Normalized EBITDA
-27.62
-12.08%
-24.65
+61.28%
-63.66
-21.01%
-52.61
Reconciled Depreciation
0.46
-2.55%
0.47
+69.42%
0.28
-73.95%
1.07
EBIT
-29.55
+51.34%
-60.73
+7.32%
-65.53
-19.16%
-54.99
Total Unusual Items
-1.47
+95.88%
-35.62
-2137.12%
-1.59
-20.97%
-1.32
Total Unusual Items Excluding Goodwill
-1.47
+95.88%
-35.62
-2137.12%
-1.59
-20.97%
-1.32
Special Income Charges
-1.47
+95.88%
-35.62
-2137.12%
-1.59
-20.97%
-1.32
Impairment Of Capital Assets
0.00
-100.00%
24.72
+1452.70%
1.59
+20.97%
1.32
Restructuring And Mergern Acquisition
1.47
-86.52%
10.90
0.00
—
Net Income
-28.92
+69.05%
-93.44
-49.07%
-62.68
-13.39%
-55.28
Pretax Income
-28.91
+69.05%
-93.40
-49.14%
-62.62
-13.31%
-55.27
Net Non Operating Interest Income Expense
1.13
-61.62%
2.95
-34.39%
4.50
+332.18%
1.04
Net Interest Income
1.13
-61.62%
2.95
-34.39%
4.50
+332.18%
1.04
Interest Income Non Operating
1.13
-61.62%
2.95
-34.39%
4.50
+332.18%
1.04
Interest Income
1.13
-61.62%
2.95
-34.39%
4.50
+332.18%
1.04
Other Income Expense
-0.49
+98.63%
-35.62
-2137.12%
-1.59
-20.97%
-1.32
Other Non Operating Income Expenses
0.98
—
—
—
Tax Provision
0.01
-71.79%
0.04
-33.90%
0.06
+353.85%
0.01
Tax Rate For Calcs
0.00
+0.00%
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
-0.31
+95.88%
-7.48
0.00
+100.00%
-0.28
Net Income Including Noncontrolling Interests
-28.92
+69.05%
-93.44
-49.07%
-62.68
-13.39%
-55.28
Net Income From Continuing Operation Net Minority Interest
-28.92
+69.05%
-93.44
-49.07%
-62.68
-13.39%
-55.28
Net Income From Continuing And Discontinued Operation
-28.92
+69.05%
-93.44
-49.07%
-62.68
-13.39%
-55.28
Net Income Continuous Operations
-28.92
+69.05%
-93.44
-49.07%
-62.68
-13.39%
-55.28
Normalized Income
-27.76
+57.49%
-65.30
-6.89%
-61.09
-12.63%
-54.24
Net Income Common Stockholders
-28.92
+69.05%
-93.44
-49.07%
-62.68
-13.39%
-55.28
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
—
-71.75
-13.89%
-63.00
+31.15%
-91.50
Basic EPS
—
-71.75
-13.89%
-63.00
+31.15%
-91.50
Basic Average Shares
—
1.30
+30.74%
1.00
+64.72%
0.60
Diluted Average Shares
—
1.30
+30.74%
1.00
+64.72%
0.60
Diluted NI Availto Com Stockholders
-28.92
+69.05%
-93.44
-49.07%
-62.68
-13.39%
-55.28
Line Item Trend 2023-12-31
Total Assets
142.60
Current Assets
104.82
Cash Cash Equivalents And Short Term Investments
102.75
Cash And Cash Equivalents
22.35
Other Short Term Investments
80.40
Prepaid Assets
—
Other Current Assets
2.07
Total Non Current Assets
37.78
Net PPE
35.28
Gross PPE
37.20
Accumulated Depreciation
-1.92
Properties
0.00
Machinery Furniture Equipment
0.77
Construction In Progress
—
Other Properties
35.97
Leases
0.46
Other Non Current Assets
2.50
Total Liabilities Net Minority Interest
53.18
Current Liabilities
19.60
Payables And Accrued Expenses
11.27
Payables
3.13
Accounts Payable
3.13
Current Accrued Expenses
8.14
Pensionand Other Post Retirement Benefit Plans Current
—
Current Debt And Capital Lease Obligation
5.43
Current Capital Lease Obligation
5.43
Current Deferred Liabilities
1.66
Current Deferred Revenue
1.66
Other Current Liabilities
1.23
Total Non Current Liabilities Net Minority Interest
33.58
Long Term Debt And Capital Lease Obligation
21.45
Long Term Capital Lease Obligation
21.45
Non Current Deferred Liabilities
12.14
Non Current Deferred Revenue
12.14
Stockholders Equity
89.42
Common Stock Equity
89.42
Capital Stock
0.06
Common Stock
0.06
Preferred Stock
0.00
Share Issued
1.14
Ordinary Shares Number
1.14
Treasury Shares Number
0.00
Additional Paid In Capital
400.69
Retained Earnings
-311.36
Gains Losses Not Affecting Retained Earnings
0.03
Other Equity Adjustments
0.03
Total Equity Gross Minority Interest
89.42
Total Capitalization
89.42
Working Capital
85.22
Invested Capital
89.42
Total Debt
26.88
Capital Lease Obligations
26.88
Net Tangible Assets
89.42
Tangible Book Value
89.42
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-28.86
+58.78%
-70.01
-10.59%
-63.30
-45.91%
-43.38
Cash Flow From Continuing Operating Activities
-28.86
+58.78%
-70.01
-10.59%
-63.30
-45.91%
-43.38
Net Income From Continuing Operations
-28.92
+69.05%
-93.44
-49.07%
-62.68
-13.39%
-55.28
Depreciation Amortization Depletion
0.46
-2.55%
0.47
+69.42%
0.28
-73.95%
1.07
Depreciation
0.46
-2.55%
0.47
+69.42%
0.28
-73.95%
1.07
Depreciation And Amortization
0.46
-2.55%
0.47
+69.42%
0.28
-73.95%
1.07
Stock Based Compensation
2.33
-65.23%
6.72
+14.08%
5.89
+8.08%
5.45
Asset Impairment Charge
0.00
-100.00%
24.86
+1461.49%
1.59
+20.97%
1.32
Operating Gains Losses
-0.01
—
—
—
Gain Loss On Sale Of PPE
-0.01
0.00
—
—
Change In Working Capital
-2.73
+57.04%
-6.35
-29.91%
-4.88
-207.24%
4.55
Change In Prepaid Assets
2.07
+644.47%
-0.38
-143.83%
0.87
+213.48%
-0.76
Change In Payables And Accrued Expense
-2.33
+70.40%
-7.86
-505.05%
1.94
-17.79%
2.36
Change In Accrued Expense
-1.81
+69.69%
-5.97
-500.74%
1.49
-68.76%
4.77
Change In Payable
-0.52
+72.66%
-1.89
-519.33%
0.45
+118.66%
-2.41
Change In Account Payable
-0.52
+72.66%
-1.89
-519.33%
0.45
+118.66%
-2.41
Change In Other Working Capital
-0.40
+74.05%
-1.53
+1.54%
-1.56
-142.84%
3.64
Change In Other Current Assets
3.13
+27.11%
2.46
+150.01%
-4.93
-241.68%
-1.44
Change In Other Current Liabilities
-5.20
-638.51%
0.97
+179.97%
-1.21
-258.32%
0.76
Investing Cash Flow
-0.10
-100.12%
80.31
+738.15%
-12.58
+80.64%
-65.01
Cash Flow From Continuing Investing Activities
-0.10
-100.12%
80.31
+738.15%
-12.58
+80.64%
-65.01
Net PPE Purchase And Sale
-0.10
+95.81%
-2.34
-123.30%
-1.05
-538.41%
-0.16
Purchase Of PPE
-0.12
+95.04%
-2.34
-123.30%
-1.05
-538.41%
-0.16
Sale Of PPE
0.02
0.00
—
—
Capital Expenditure
-0.12
+95.04%
-2.34
-123.30%
-1.05
-538.41%
-0.16
Net Investment Purchase And Sale
0.00
-100.00%
82.64
+816.33%
-11.54
+82.21%
-64.84
Purchase Of Investment
0.00
+100.00%
-47.95
+60.83%
-122.42
-88.80%
-64.84
Sale Of Investment
0.00
-100.00%
130.59
+17.77%
110.89
0.00
Financing Cash Flow
4.27
-49.91%
8.53
-87.01%
65.69
-31.75%
96.26
Cash Flow From Continuing Financing Activities
4.27
-49.91%
8.53
-87.01%
65.69
-31.75%
96.26
Net Common Stock Issuance
5.00
-43.31%
8.82
-87.26%
69.24
-31.10%
100.50
Proceeds From Stock Option Exercised
0.00
-100.00%
0.00
-97.09%
0.10
+1187.50%
0.01
Net Other Financing Charges
-0.73
-150.34%
-0.29
+92.06%
-3.65
+13.94%
-4.25
Changes In Cash
-24.68
-231.12%
18.82
+284.61%
-10.20
+15.96%
-12.13
Beginning Cash Position
42.57
+79.28%
23.75
-30.04%
33.94
-26.33%
46.08
End Cash Position
17.89
-57.98%
42.57
+79.28%
23.75
-30.04%
33.94
Free Cash Flow
-28.98
+59.95%
-72.35
-12.43%
-64.35
-47.77%
-43.55
Amortization Of Securities
0.00
+100.00%
-2.28
+34.90%
-3.50
-610.57%
-0.49
Common Stock Issuance
5.00
-43.31%
8.82
-87.26%
69.24
-31.10%
100.50
Issuance Of Capital Stock
5.00
-43.31%
8.82
-87.26%
69.24
-31.10%
100.50
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category